Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Nanobiotix Appoints Dr. Alain Herrera to the Supervisory Board

Published: Thursday, February 14, 2013
Last Updated: Thursday, February 14, 2013
Bookmark and Share
Former Global Oncology Head from Sanofi-Aventis joins the Nanobiotix team.

Nanobiotix has announced that Dr. Alain Herrera joins its Supervisory Board, succeeding Thierry Chopin and Isabelle Bou Antoun in their roles, as part of a planned Supervisory Board succession.

Dr. Herrera joins Nanobiotix Supervisory Board with more than 25 years of experience in the pharmaceutical industry with a strong focus in oncology drug development and marketing.

Before setting up his own oncology consultancy - Alain Oncologie Consulting (AOC) -, he headed the Oncology business at Sanofi-Aventis for ten years, where he was Vice President for the Global Oncology Business Strategy and Development (2007-2008) and Head of the Global Oncology Franchise (1998-2007).

He contributed to the worldwide registration of Oxaliplatin (Eloxatin®) and Rasburicase (Fasturtec®/Elitek®), as well as the Gastric and Head & Neck indications for Docetaxel (Taxotere®).

His previous responsibilities within the pharmaceutical industry included the roles of Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories and Head of the Oncology Platform at Roger Bellon (Rhône Poulenc).

In addition to these roles, since 1991, Dr. Herrera has been a Hematologist Consultant at Antoine Beclere Hospital.

Dr. Herrera said: “Over recent years, Nanobiotix’s nanomedicine technology has repeatedly demonstrated its significant potential for optimizing the efficacy of radiotherapy, a treatment currently used for about 60% of cancer patients and a key component of the treatment strategy in curative setting. I'm both delighted and privileged to be able to play a part in helping Nanobiotix to deliver its objectives and to overcome the challenges that lie ahead. I look forward to working with the Nanobiotix team.”

“We welcome Dr. Alain Herrera to the Supervisory Board. Pioneer of industrial oncology, his business and pharmaceutical industry experience will add important expertise to the Board,” said Laurent Levy, CEO of Nanobiotix.

Levy continued, “Alain has been a member of the Scientific Advisory Board of Nanobiotix over the past years, so he already has a thorough knowledge of its business and its technology. We believe his skills and oncology leadership will assist us in fulfilling our strategic business objectives and to progress our international development.”

Laurent Levy added: "I would also like to thank Thierry Chopin and Isabelle Bou Antoun for the contribution they have made over the last years of service, helping to position Nanobiotix for a promising future."

The nomination of Dr. Herrera will be submitted to the approval of the next general shareholders’ meeting in accordance with applicable law.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply
Mr Otin will be responsible for the manufacturing plans to move NBTXR3 from clinical trials.
Thursday, April 17, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
Nanobiotix Strengthens its Supervisory Board for the Next Stage of its Development
Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board.
Thursday, January 30, 2014
Nanobiotix Strengthens its Supervisory Board for the Next Stage of its Development
Anne-Marie GRAFFIN and Enno SPILLNER join the Supervisory Board.
Thursday, January 30, 2014
Nanobiotix 2013 Review: Significant Corporate and Clinical Progress
Company announces its prospective financial communications calendar for the fiscal year 2014.
Friday, January 10, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.
Friday, July 05, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
NANOBIOTIX Announced Positive Phase I Results of NBTXR3
Company’s NBTXR3 achieves clinical milestone reaching proof-of-concept in phase I trial of STS.
Tuesday, June 04, 2013
Dr. Laurent Levy, CEO of Nanobiotix, Receives UB Entrepreneurship Award
Nanobiotix announces that its CEO and co-founder, Dr. Laurent Levy, has received the award at the Annual Inventors and Entrepreneurs Reception at the University at Buffalo (UB).
Thursday, April 04, 2013
Nanobiotix Selected to Present at Future Leaders in the Biotech Industry Conference
Laurent Levy to give a Company Presentation at the 20th Annual Future Leaders in New York.
Wednesday, March 20, 2013
Scientific News
Genetic Defences of Bacteria Don’t Aid Antibiotic Resistance
Genetic responses to the stresses caused by antibiotics don’t help bacteria to evolve a resistance to the medications, according to a new study by Oxford University researchers.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
Cell's Waste Disposal System Regulates Body Clock Proteins
New way to identify interacting proteins could identify potential drug targets.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
How a Molecular Motor Untangles Protein
Diseases such as Alzheimer’s, Parkinson’s and prion diseases, all involve “tangled” proteins.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos